Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 255,203 | 265,876 | 133,810 | 144,687 | 54,518 |
| Other current assets | 0 | 0 | 0 | 0 | 2,824 |
| TOTAL | $255,982 | $267,726 | $136,416 | $148,517 | $58,539 |
| Non-Current Assets | |||||
| PPE Net | 854 | 724 | 739 | 781 | 822 |
| Other Non-Current Assets | 894 | 993 | 1,091 | 1,140 | 1,231 |
| TOTAL | $1,748 | $1,717 | $1,830 | $1,921 | $2,053 |
| Total Assets | $257,730 | $269,443 | $138,246 | $150,438 | $60,592 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,008 | 2,149 | 1,716 | 4,852 | 2,426 |
| Accrued Expenses | 5,506 | 4,612 | 4,697 | 3,042 | 6,022 |
| TOTAL | $8,950 | $7,184 | $6,825 | $8,294 | $8,836 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 408 | 538 | 663 | 783 | 901 |
| TOTAL | $408 | $538 | $663 | $783 | $901 |
| Total Liabilities | $9,358 | $7,722 | $7,488 | $9,077 | $9,737 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 23,297 | 23,271 | 20,188 | 20,173 | 20,149 |
| Common Shares | 2 | 2 | 2 | 2 | 1 |
| Retained earnings | -80,896 | -65,011 | -54,335 | -42,299 | -31,542 |
| Other shareholders' equity | 0 | 0 | 0 | 0 | 75,722 |
| TOTAL | $248,372 | $261,721 | $130,758 | $141,361 | $50,855 |
| Total Liabilities And Equity | $257,730 | $269,443 | $138,246 | $150,438 | $60,592 |